Hori Atsushi, Dejima Ikuo, Hori Shinichi, Oka Shuto, Nakamura Tatsuya, Ueda Shota
Institute for Image Guided Therapy, Izumisano 598-0047, Japan.
Department of Radiology, Wakayama Medical University, Wakayama 641-8509, Japan.
Life (Basel). 2022 Jul 19;12(7):1078. doi: 10.3390/life12071078.
The treatment efficacy of the transarterial approach to lung cancer is evaluated.
A total of 98 patients with advanced lung cancer or recurrent lung cancer after the standard therapies were enrolled retrospectively. The bronchial arteries and mediastinal branches from the subclavian artery were selected by a microcatheter. Immediately after the selective arterial infusion of anti-neoplastic agents, embolization with a spherical embolic material was carried out. Local tumor effects and overall survival were evaluated.
The mean reduction rate was 17.9%, with 24.2% for partial remission and with 2.1% for progression disease. The rate of stable disease was 72.6%. The response rate was 25.3%, and the disease control rate was 97.9%. The median survival time (MST) was 11.4 months, the 1-year survival rate was 45.2%, and the 2-year survival rate was 35.6%. Although it is insignificant, the MST for 51 adenocarcinomas was higher than that of 29 squamous cell carcinomas (18.6 months and 9.4 months, respectively). The local extension of tumors related to a better prognosis, though it was not significant. Lymph node metastases and distant metastases were poor prognostic factors. No major complications nor treatment-related mortalities were found in this study.
The transarterial treatment for lung cancer should be considered as a treatment option when the other treatments were not indicated both in initial cases and in recurrent cases.
评估经动脉途径治疗肺癌的疗效。
回顾性纳入98例标准治疗后出现晚期肺癌或复发性肺癌的患者。通过微导管选择支气管动脉和锁骨下动脉的纵隔分支。在选择性动脉内注入抗肿瘤药物后，立即用球形栓塞材料进行栓塞。评估局部肿瘤效应和总生存期。
平均缩小率为17.9%，部分缓解率为24.2%，疾病进展率为2.1%。疾病稳定率为72.6%。缓解率为25.3%，疾病控制率为97.9%。中位生存期（MST）为11.4个月，1年生存率为45.2%，2年生存率为35.6%。虽然差异不显著，但51例腺癌的MST高于29例鳞状细胞癌（分别为18.6个月和9.4个月）。肿瘤的局部扩展与较好的预后相关，尽管不显著。淋巴结转移和远处转移是不良预后因素。本研究未发现重大并发症或与治疗相关的死亡。
在初始病例和复发病例中，当其他治疗均不适用时，应考虑将经动脉治疗作为肺癌的一种治疗选择。
